<DOC>
	<DOCNO>NCT00000846</DOCNO>
	<brief_summary>To evaluate safety immunogenicity 2 different HIV-1 peptide candidate vaccine , UBI HIV-1 MN PND peptide immunogen UBI microparticulate monovalent HIV-1 MN branch peptide administer sequentially 2 different route immunization , parental priming follow oral boosting .</brief_summary>
	<brief_title>A Phase I Trial To Evaluate Safety Immunogenicity UBI HIV-1MN PND Peptide Immunogen , Given IM Injection , Combination With UBI Microparticulate Monovalent HIV-1 MN Branched Peptide Given Orally , HIV-1 Uninfected Volunteers .</brief_title>
	<detailed_description>After prescreening , volunteer randomize Group I Group II . Each group contain 16 volunteer . At least 5 volunteer group must woman . At month 0 volunteer receive multivalent HIV-1 peptide immunogen placebo . Group I receive injection deltoid Group II receive anterior thigh . At month 1 , 2 8 patient receive microparticulate monovalent HIV-1 peptide placebo . Follow conduct .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria Patients must : Healthy . Negative ELISA HIV . Negative Hepatitis B surface antigen . Normal urine dipstick . Normal history physical exam . Availability followup plan duration study ( 60 week ) . Risk Behavior : Required : Lower intermediate risk sexual behavior define AVEG . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Medical psychiatric condition occupational responsibility preclude subject compliance protocol . Active syphilis . NOTE : If serology document false positive due remote ( &gt; 6 month ) treat infection , volunteer eligible . Active tuberculosis . NOTE : Volunteers positive PPD normal chest Xray show evidence TB require INH therapy eligible . Patients follow prior condition exclude : History immunodeficiency , chronic illness , malignancy autoimmune disease . History anaphylaxis serious adverse reaction vaccine . History inflammatory gastrointestinal disease , celiac disease intestinal malignancy . History acute gastroenteritis within past month gastrointestinal surgery within past 12 month . Prior Medication : Excluded : History use immunosuppressive medication . Live attenuate vaccine within 60 day study . NOTE : Medically indicate subunit kill vaccine ( e.g. , influenza , pneumococcal ) exclusionary give least 2 week away HIV immunization . Use experimental agent within 30 day prior study . Receipt blood product immunoglobulin past 6 month . Prior receipt HIV vaccine placebo recipient HIV vaccine trial . Risk Behavior : Excluded : Subjects identifiable high risk behavior HIV infection determine screen questionnaire design identify risk factor HIV infection . History injection drug use within last 12 month enrollment . Higher risk sexual behavior define AVEG .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2002</verification_date>
	<keyword>Vaccines , Synthetic</keyword>
	<keyword>HIV-1</keyword>
	<keyword>AIDS Vaccines</keyword>
	<keyword>HIV Seronegativity</keyword>
	<keyword>HIV Preventive Vaccine</keyword>
</DOC>